RevitalVision's break through technology is the only clinically proven and FDA approved therapy with efficacy claim for improving vision in adult amblyopia, effecting 2%-5% of the world population. Amblyopia is the number 1 cause for impaired vision from infancy until the age of 40 and is considered untreatable after the age of 9.
The technology is also effective in improving vision in a number of other visual impairments and conditions. RevitalVision provides additional significant vision improvement beyond what is currently available by only treating the eyes. The average vision improvement is 2.5 lines on the visual acuity chart, and 100% in contrast sensitivity (about 20% - 25% vision improvement). Most amblyopic patients also improve stereo acuity and binocular function.
Our team comprises of medical experts and multi-disciplinary professionals that together addressing the need of hundreds of millions of people worldwide suffering from different visual impairments and who, until now, had no effective alternative solution to improve their condition.
Founder & CEO
Over 20 years’ experience in senior executive positions in the medical device industry. Past positions includes sales manager
at J&J medical, Business Unit Manager at Boston Scientific, VP sales Asia Pacific at Flight Medical Innovations Ltd.
Yair holds a Bachelor’s degree in political science from Bar Ilan University, and studied for MBA at the Israeli branch of
Henley Brunel business college of West London.
Senior Software Engineer. Graduated software engineering and MBA studies from the TECHNION – Israel Institute of Technology. Served as a software engineer in the IDF (Israel Defense Forces), followed by a senior software engineer position at the Israeli Prime Minister office.
Clinical Service & Sales Manager, Israel
A Certified Optometrist graduated Optometry studies at Hadassah academic college of optometry and visual science. Lena has extensive clinical experience in clinical optometry, and with RevitalVision therapy. Lena specializes in geriatric and in low vision patients.
Clinical & Sales Specialist
Founder and former CEO of Orca Surgical, an ophthalmic medical device startup. A Certified Optometrist, graduated from the Institute for Research & Studies in Optics and Optometry, in Vidi, Italy. Yariv is well- experienced & well connected to Industry KOL’s.
Experienced Medical Device executive, with 3 consecutive exits. Current CEO of Orthospace, that was sold to Stryker (2019) for 220$ million. Four years earlier, Itay sold Orthospace to an American investment fund – Innova Health. Itay founded and managed Surgical Structure Ltd, and sold the company to Devol Inc. Itay holds a BA in Economics from Ruppin Academy College, and MBA from the College of Management, Israel.
Scientific & Clinical Advisor
Senior pediatric ophthalmologist surgeon. Head of strabismus & pediatric ophthalmology unit at Assaf Harofe Medical Center, Israel. Former president of the Israeli association of strabismus and pediatric ophthalmology.
Prof. (Full member) in Tel Aviv University. Member of the managing committee of the World Society of Pediatric Ophthalmology and Strabismus. A member of the American – Academy of Pediatric Ophthalmology and Strabismus.
Dr. Amir Belson is a serial entrepreneur, a founder of 12 different companies. He is the founder of Neoguide Systems, a robotic endoscopy company that was acquired by Intuitive Surgical in 2009, Vascular Pathways, a vascular intervention company which was acquired by C R Bard in 2014, Zipline Medical, a wound closure company which was acquired by Stryker in 2019, Qool Therapeutics, a minimally invasive therapeutic hypothermia technology company, Radiaction Medical, a CE mark approved radiation protection medical device company, Embolibe, which develops proprietary total body embolic protection technology, Modular Surgical which develops new minimally invasive surgery technology, and PAFA, that develops atrial fibrillation ablation technology.
Dr. Belson also serves as board director of Rambam Tech, Plantera Lab, Relimetrics and QT Vascular.
Belson graduated cum laude from the school of medicine of the Technion, Israel Institute of Technology, in Haifa, Israel. He did his pediatric residency at Dana Children’s Hospital in Tel Aviv and his pediatric nephrology fellowship at Lucile Packard Children’s Hospital at Stanford University. Belson also spent one year as a research fellow with the Bio-Design Innovation Program at Stanford.
He is the author of 34 medical papers and abstracts and has more than 500 issued and pending patents.